|Dr. Jethro Holter||Chief Exec. Officer||1.49M||N/A||1972|
|Mr. BÃ¸rge SÃ¸rvoll||Chief Financial Officer||1.33M||N/A||1975|
|Mr. Alexander Johann Bjorna||Director of IP & Bus. Devel.||N/A||N/A||N/A|
ArcticZymes Technologies ASA develops, manufactures, and markets immunomodulating beta-glucans and recombinant enzymes in Norway, Europe, Asia, Australia, Africa, and the Americas. It operates through two segments, Enzymes and Beta-Glucans. The company provides recombinant enzymes that are primarily derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics, and therapeutics. It offers shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing (NGS) processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of DNA from RNA samples; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; salt active nuclease for the removal of nucleic acids during manufacturing of vaccines, viruses, recombinant proteins, and other reagents; and ligases for joining DNA fragments. The company also provides immunomodulating beta-glucans products for the wound care, animal and consumer health, and adjuvants markets. It offers Woulgan wound gel; M-Glucan, a natural immune-stimulating product for fish and animal feed; and M-Gard, a natural immune-stimulating ingredients to enhance physical health. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in TromsÃ¸, Norway.
ArcticZymes Technologies ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.